Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market

 
• By Joseph Haas
Diabetes
Lilly's initial Phase III data for its dual GIP/GLP-1 agonist look competitive

More from Clinical Trials

More from R&D